%0 Journal Article %T The influence of pemetrexed-based continuous maintenance therapy on survival of locally advanced and metastatic lung adenocarcinoma %A Huang, Yu %A Wang, Ying %A Hu, Dandan %A Chen, Lingjuan %A Zhang, Ruiguang %A Cheng, Shishi %A Wu, Gang %A Dong, Xiaorong %J Annals of Translational Medicine %D 2019 %B 2019 %9 %! The influence of pemetrexed-based continuous maintenance therapy on survival of locally advanced and metastatic lung adenocarcinoma %K %X Background: Patients may receive delayed maintenance therapy (stopping interval over 21 days) due to multi factors in the real-life setting. This retrospective study aims to collect data of pemetrexed-based continuous maintenance therapy, evaluate the impact of prolonged interval periods on clinical outcomes. Methods: A total of 168 previously untreated stage IIIB or IV lung adenocarcinoma patients received induction chemotherapy with pemetrexed-platinum (PP) with or without antiangiogenesis inhibitors (bevacizumab or rh-endostatin) every 3 weeks for 4–6 cycles. Among them, 112 patients who did not show progression after induction chemotherapy completion were enrolled. Results: Seventy of the 112 patients received continuous maintenance therapy with pemetrexed with or without antiangiogenesis inhibitors until disease progression; 42 patients did not receive continuous maintenance therapy. Multivariate analysis revealed that only lack of maintenance therapy was independently associated with shorter progression-free survival (PFS) [HR, 4.516 (2.332–8.744), P vs . 6.8 months, P vs . 18.0 months, P=0.001) compared with those in the non-maintenance group. Conclusions: Extending maintenance intervals is feasible and continuous maintenance therapy could offer survival benefit in patients who did not show progression after first-line induction treatment for lung adenocarcinoma. %U https://atm.amegroups.org/article/view/30762 %V 7 %N 20 %P 524 %@ 2305-5847